Cyclophosphamide and VP-16-213 with or without cisplatin in squamous cell and small cell lung cancers

R. T. Eagan, S. Frytak, W. C. Nichols, J. N. Ingle, E. T. Creagan, L. K. Kvols

Research output: Contribution to journalArticle

11 Scopus citations

Abstract

Forty-seven patients with squamous cell or small cell lung cancer (28 [16%] of whom had cardiac disease too severe to permit the use of doxorubicin) were treated with cyclophosphamide and VP-16-213 with or without cisplatin. Four of 11 patients with squamous cell (36%) and 19 of 24 patients with small cell (79%) cancers had tumor regressions (eight complete regressions) on the three-drug regimen. Median survival times for the 31 patinets with small cell lung cancer were 9 months for those with extensive disease and 12.2 months for those with limited disease. The data suggest that the roles of VP-16-213 and cisplatin need further evaluation in these cell types and that doxorubicin may not be mandatory for successful treatment of squamous cell and small cell lung cancers.

Original languageEnglish (US)
Pages (from-to)453-458
Number of pages6
JournalCancer Treatment Reports
Volume65
Issue number5-6
StatePublished - Aug 29 1981

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Cyclophosphamide and VP-16-213 with or without cisplatin in squamous cell and small cell lung cancers'. Together they form a unique fingerprint.

  • Cite this

    Eagan, R. T., Frytak, S., Nichols, W. C., Ingle, J. N., Creagan, E. T., & Kvols, L. K. (1981). Cyclophosphamide and VP-16-213 with or without cisplatin in squamous cell and small cell lung cancers. Cancer Treatment Reports, 65(5-6), 453-458.